PLUR Pluri Inc. Net earnings per share for the last 12 months

Public company logo of pluri-biotech.com (PLUR)

Pluri Inc. is implementing a unique 3D technology for growing placental cells to create large-scale batches of living medicines. The profit per unit trend over the last 12 months illustrates the dynamics of this process, where the value remains at -2.67. Despite pressure from traditional pharmacology, a strong team of Israeli scientists provides the company with a sustainable technological advantage in biomedicine.

PLUR (Pluri Inc) Net earnings per share (EPS TTM) history from 04/28/2023 to 11/14/2026

Analytical breakdowns and data insights for company Pluristem Therapeutics (PLUR)

- stock price and consensus target price:
Stock Price Pluri Inc|PLUR - Average Forecast Price
- market capitalization data:
Market Valuation Pluri Inc.|PLUR - Aggregate Business Value
- balance sheet net asset value indicators:
Book Value per Share Pluri|PLUR - Book Capitalization|Market Capitalization to Book Value Ratio pluri-biotech.com|PLUR - Aggregate Company Assets
- business debt structure and liquidity details:
Debt to Equity Pluri Inc.|PLUR - Long-Term Liabilities to Capital|Short-Term Debt to Equity Pluri Inc|PLUR - Company Debts|Debts to Book Capitalization Pluri Inc.|PLUR - Long-Term Debt Volume|Company Short-Term Debt Pluri|Quick Liquidity pluri-biotech.com
- net income and valuation multiples indicators:
PLUR - Net Income|Expected Profit Pluri Inc.|PLUR - Market Cap to Net Income|Future Price to Earnings Pluri Inc|PLUR - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Pluri Inc.|PLUR - Operating profit EBITDA|Earnings per share for the last twelve months Pluri|PLUR - Earnings per share for the trailing year|Quarterly EPS earnings growth pluri-biotech.com|PLUR - Expected net earnings per share growth this year|Expected earnings per share growth for next year Pluri Inc.
- sales and revenue data:
PLUR - Company Sales Revenue|Projected Sales Volume Pluri Inc|PLUR - Price-to-Revenue Coefficient|Price-to-Projected Revenue Ratio Pluri Inc.
Fundamental company valuation:pluri-biotech.com (PLUR)
Mass-produced product of Pluri Inc

Earnings per share (EPS TTM) reflects the portion of profit attributable to a single security over the last twelve months. This metric allows for an assessment of the asset's real return by excluding the impact of the total issuance volume. By analyzing changes in the rolling annual EPS, an investor determines the business's resilience to market downturns. For Pluri Inc. (PLUR), this indicator confirms the effectiveness of commercializing cell technologies through government and agro-industrial partnerships. The synergy between biotech and foodtech directly influences the dynamics of this fundamental metric.

Competitors of Pluri Inc.

Ascendis Pharma A/S - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months madrigalpharma.com|CORT (Corcept Therapeutics Incorporated) - Net earnings per share for the last 12 months|RYTM: Earnings per share for the last four quarters|AKRO (Akero Therapeutics Inc) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Metsera Therapeutics|Net earnings per share (EPS TTM) MLTX|Earnings per share for the last twelve months CRNX (crinetics.com)|Earnings per share for the last twelve months NewAmsterdam Pharma Company N.V. NAMS|Soleno Therapeutics Inc (SLNO) - Net earnings per one share for the last twelve months|FOLD - Earnings per share for the last twelve months|ETNB: Earnings per share for the last twelve months|AGIO: Net earnings per share (EPS TTM)|GPCR - Net earnings per share for the last four quarters|Earnings per share for the last twelve months MiMedx|Rezolute Inc (RZLT) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Lexicon Pharma (LXRX)|Net earnings per share for the last 12 months MBX Corp MBX|Earnings per share for the last twelve months Altimmune, Inc. ALT|AARD (aardvarktherapeutics.com) - Earnings per one share for the last 12 months|SGMT - Earnings per share for the last twelve months|BIOA: Earnings per share for the last twelve months|BMEA (Biomea) - Net earnings per share for the last 12 months|Quince Therapeutics, Inc. (QNCX) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months Fractyl Health, Inc.|VTVT: Earnings per share for the trailing year|Net earnings per share (EPS TTM) ATPC|Net earnings per share for the last four quarters synlogictx.com|Lipocine Corp - Net earnings per share for the last 12 months|Earnings per share for the trailing year MTNB|Spruce Biosciences, Inc. - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters galecto.com GLTO|Carmell (CTCX) - Earnings per share for the last twelve months|Earnings per share for the last 12 months LUMO|ONVO (Organovo Holdings Inc) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Radius Pharmaceuticals (RDUS)